Transaction (JO:) Anticipated to Shut within the Coming Days
SOMERSET, N.J. & COPENHAGEN, Denmark–(BUSINESS WIRE)–Catalent, Inc. (Catalent (NYSE:), NYSE: CTLT), a pacesetter in enabling the event and provide of higher remedies for sufferers worldwide, and Novo Holdings A/S (Novo Holdings), a worldwide life sciences funding agency, at present introduced that the businesses have fulfilled all regulatory closing circumstances for his or her pending transaction. The businesses now anticipate to shut the transaction within the coming days.
Right now represents an essential step in our transition to non-public possession underneath Novo Holdings, a number one life sciences funding agency, stated Alessandro Maselli, President and Chief Govt Officer of Catalent. As we method transaction shut, I need to thank the Catalent group for all their exhausting work and share my pleasure for our firm’s brilliant future. With the help of Novo Holdings and entry to further assets, Catalent shall be well-positioned to drive innovation and improve choices for the good thing about prospects and the sufferers they serve, in the end accelerating our technique to create worth for stakeholders.
We’re happy to have achieved this newest milestone, which we consider displays the numerous advantages the proposed transaction is predicted to ship, stated Jonathan Levy, Senior Accomplice, Novo Holdings. As we close to shut, we’re obsessed with partnering with and supporting the Catalent group in its mission to drive innovation within the healthcare system and enhance affected person outcomes.
For extra info related to the transaction, please go to transaction.catalent.com.
Advisors
Citi and J.P. Morgan served as monetary advisors to Catalent. Skadden, Arps, Slate, Meagher & Flom LLP served as authorized advisor to Catalent and Jones Day served as authorized advisor to the Catalent Board of Administrators. Morgan Stanley & Co (NYSE:). LLC served as monetary advisor to Novo Holdings. Goodwin Procter LLP and Linklaters LLP served as authorized advisors to Novo Holdings. Arnold & Porter Kaye Scholer LLP and Davis Polk & Wardwell LLP served as authorized advisors to Novo Nordisk (NYSE:).
About Novo Holdings A/S
Novo Holdings is a holding and funding firm that’s answerable for managing the property and the wealth of the Novo Nordisk Basis. The aim of Novo Holdings is to enhance individuals’s well being and the sustainability of society and the planet by producing enticing long-term returns on the property of the Novo Nordisk Basis.
Wholly owned by the Novo Nordisk Basis, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (previously Novozymes (OTC:) A/S) and manages an funding portfolio with a long-term return perspective. Along with managing a broad portfolio of equities, bonds, actual property, infrastructure and personal fairness property, Novo Holdings is a world-leading life sciences investor. By its Seed, Enterprise, Development, Asia, Planetary Well being and Principal Investments groups, Novo Holdings invests in life science corporations in any respect levels of growth. As of year-end 2023, Novo Holdings had whole property of EUR 149 billion. www.novoholdings.dk
About Catalent, Inc.
Catalent, Inc. (NYSE: CTLT), is a worldwide chief in enabling pharma, biotech, and shopper well being companions to optimize product growth, launch, and full life-cycle provide for sufferers around the globe. With broad and deep scale and experience in growth sciences, supply applied sciences, and multi-modality manufacturing, Catalent is a most popular trade accomplice for personalised medicines, shopper well being model extensions, and blockbuster medication. Catalent helps speed up over 1,500 accomplice growth packages and launch over 150 new merchandise yearly. Its versatile manufacturing platforms at over 50 world websites provide almost 70 billion doses of almost 8,000 merchandise yearly. Catalent’s knowledgeable workforce of roughly 17,000 consists of greater than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, the corporate generated roughly $4.4 billion in income in its 2024 fiscal 12 months. For extra info, go to www.catalent.com.
Ahead-Wanting Statements
This press launch, and any associated oral statements, could embody each historic and forward-looking statements and steerage. All statements apart from statements of historic truth, are, or could also be deemed to be, forward-looking statements throughout the that means of Part 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Trade Act of 1934, as amended. These forward-looking statements typically will be recognized by means of statements that embody phrases reminiscent of consider, anticipate, anticipate, intend, estimate, plan, mission, predict, hope, foresee, possible, could, may, goal, will, would, or different phrases or phrases with comparable meanings. Equally, statements that describe Catalent’s aims, plans, or objectives are, or could also be, forward-looking statements. These statements are based mostly on present expectations of future occasions. If underlying assumptions show inaccurate or unknown dangers or uncertainties materialize, precise outcomes may fluctuate materially from Catalent’s expectations, projections, and steerage. Among the components that would trigger precise outcomes to vary materially from forward-looking statements embody, however will not be restricted to, the pending merger of Catalent with an affiliate of Novo Holdings (the Merger), the completion of the Merger on anticipated phrases and timing, together with acquiring antitrust and different regulatory approvals and clearances, the satisfaction of different circumstances to the completion of the Merger, potential litigation regarding the Merger that could possibly be instituted by or towards Catalent, Novo Holdings or their respective associates, administrators or officers, together with the consequences of any outcomes associated thereto, the chance that disruptions from the Merger will hurt Catalent’s relationships, and sure restrictions through the pendency of the Merger which will influence Catalent’s potential to pursue enticing enterprise alternatives or strategic transactions.
These forward-looking statements communicate solely as of the date of this press launch or as of the date they’re made, and Catalent doesn’t undertake to and particularly disclaims any obligation to publicly launch the outcomes of any updates or revisions to those forward-looking statements which may be made to replicate future occasions or circumstances after the date of such statements or to replicate the prevalence of anticipated or unanticipated occasions.
View supply model on businesswire.com: https://www.businesswire.com/information/dwelling/20241213700784/en/
Catalent
Investor:
Paul Surdez
+1 (732) 537-6325
buyers@catalent.com
Media:
Laura Hortas
+1(609) 240-7025
media@catalent.com
Novo Holdings
(World inquiries) Marie-Louise Jersin, Senior Communications Accomplice
(US inquiries) Dora Gonzalez, Public Relations Specialist
novoholdingsmedia@novo.dk
Supply: Catalent, Inc.
